



Agile Therapeutics  
Investor Relations Department  
101 Poor Farm Road  
Princeton, NJ 08540  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

#### NASDAQ: AGRX

Last Trade:	5.19
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	-0.18 <span style="color: red;">↓</span> (-3.352%)
Day Range	5.06 - 5.37
52-Week Range	1.82 - 8.15
Volume	208,626

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## Stock Performance



## Press Releases [\[ View all \]](#)

Jun 27, 2017

[Agile Therapeutics Resubmits New Drug Application \(NDA\) for its Transdermal Contraceptive Patch, Twirla®](#)

May 8, 2017

[Agile Therapeutics Reports First Quarter 2017 Financial Results](#)

May 6, 2017

[Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017](#)

May 3, 2017

[Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists](#)

Apr 27, 2017

[Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women's Health](#)

## Financials [\[ View all \]](#)

Mar 15, 2017

[Annual Report \(10-K\)](#)

Apr 24, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)